MedTrace Logo

Effect of rhBNP on CMD in Patients With STEMI After PPCI

NCT05723315 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2023-02-10

No results posted yet for this study

Summary

The target population of this interventional study was STEMI patients. Primary discussion: Early rhBNP reduces microcirculation obstruction in STEMI patients undergoing primary PCI

Conditions

  • STEMI

Interventions

DRUG

recombinant human B-type natriuretic peptide

The recombinant human B-type natriuretic peptide produces physiological effects by imitating endogenous B-type natriuretic peptide

Sponsors & Collaborators

  • Henan Institute of Cardiovascular Epidemiology

    lead OTHER

Principal Investigators

  • Muwei Li, MD · Fuwai central China cardiovascular hospotial

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-20
Primary Completion
2024-12-20
Completion
2025-12-20

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05723315 on ClinicalTrials.gov